淋巴瘤CAR T细胞治疗前癌症恶病质与体重下降独立关联不良结局
该回顾性单中心队列研究纳入2017至2023年接受CAR T细胞治疗的259例淋巴瘤患者,发现治疗前3个月内体重指数下降>5%者(均符合癌症恶病质定义之一)疾病负荷和炎症参数更高,且在多因素分析中体重下降与更差缓解率、总生存期和无事件生存期独立相关。
要点
- CAR T前3个月内BMI下降>5%者疾病负荷及CRP、铁蛋白、IL-6、TNF-α更高。
- 体重下降组3级及以上神经毒性和早期血液毒性发生率更高,但多因素校正后差异不显著。
- 体重下降是CAR T治疗后缓解率、总生存期和无事件生存期不良的独立预后因素。
核心结论
- CAR T细胞治疗前3个月内体重下降是独立的不良预后因素,可能是可干预的警示信号,需进一步研究。
研究设计与样本
- 回顾性单中心队列研究,纳入2017至2023年接受CAR T细胞治疗的259例淋巴瘤患者。
主要发现
- 体重下降组(CAR T前3个月内BMI下降>5%,均符合癌症恶病质定义之一)在淋巴细胞清除和CAR T输注时疾病负荷及炎症参数(C反应蛋白、铁蛋白、白介素-6、肿瘤坏死因子α)更高。
- 体重下降组3级及以上神经毒性和早期血液毒性发生率更高,但多因素校正后未观察到这些效应。
- 单因素和多因素分析均显示体重下降组缓解率、总生存期和无事件生存期更差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell therapy has transformed the care of lymphoma, yet many patients relapse. Several prognostic markers have been associated with CAR T-cell outcomes, such as tumor burden, response to bridging chemotherapy, and laboratory parameters at the time of lymphodepletion or infusion. The effect of cancer cachexia and weight loss before CAR T cells on toxicity and outcomes is not well understood. Here, we present a retrospective single-institution cohort study of 259 patients with lymphoma treated with CAR T cells between 2017 and 2023. We observed that patients with >5% decrease in their body mass index in the 3 months preceding CAR T-cell treatment (weight loss group; all meeting one of the commonly accepted definitions of cancer cachexia) had higher disease burden and inflammatory parameters (C-reactive protein, ferritin, interleukin-6, and tumor necrosis factor α) at the time of lymphodepletion and CAR T-cell infusion. Patients with weight loss experienced higher rates of grade 3+ neurotoxicity and early hematotoxicity, but those effects were not seen upon multivariable adjustment. However, in both univariate and multivariable analysis, patients with weight loss had worse response rates, overall survival, and event-free survival, indicating that weight loss is an independent poor prognostic factor. Our data suggest that weight loss in the 3 months preceding CAR T-cell therapy represents a worrisome "alarm signal" and a potentially modifiable factor, alongside tumor burden and inflammation, and warrants further investigation in patients treated with CAR T-cell therapy.
引用
- Valtis YK, Devlin S, Shouval R, et al. Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes. Blood Adv. 2025. PMID: 39471490. doi:10.1182/bloodadvances.2024014555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。